Exploring a new target in cancer therapy related to the proline cycle
Investigating the Proline Cycle as a Potential Cancer Therapy Target
This study is looking at a process in cancer cells that helps them grow and survive, and it's trying to find new ways to stop that by testing small molecules that could become new cancer treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Missouri-Columbia NIH-funded |
| Lab location | 1 site (Columbia, United States) |
| Project ID | NIH-10981164 on NIH RePORTER |
What this research studies
This research investigates the proline cycle, a metabolic pathway that influences how cancer cells grow and survive. By focusing on specific enzymes involved in this cycle, the study aims to identify potential drug targets that could be used to develop new cancer therapies. The researchers will create and test small molecules that can inhibit these enzymes, with the goal of disrupting cancer progression. Initial findings from cellular and animal models have shown promise, indicating that this approach could lead to effective treatments for cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with metastatic breast cancer or other cancers where the proline cycle is upregulated.
Not a fit: Patients with non-cancerous conditions or those whose cancers do not involve the proline cycle may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that specifically target cancer cell metabolism, potentially improving treatment outcomes for patients.
How similar studies have performed: Other research has shown success in targeting metabolic pathways in cancer, suggesting that this approach could be promising.
Where this research is happening
Columbia, United States
- University of Missouri-Columbia — Columbia, United States (Active)
Researchers
- Principal investigator: Tanner, John J — University of Missouri-Columbia
- Study coordinator: Tanner, John J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.